Accuitis is focused on developing innovative therapeutics aimed at addressing underserved diseases, particularly through the modulation of mitochondrial functions. Their lead compound, ACU-D2, targets systemic scleroderma by enhancing the expression of Sirtuin 3 (SIRT3), a mitochondrial deacetylase that plays a crucial role in mitigating fibrosis. Preclinical studies have shown that ACU-D2 can inhibit TGF-ß-induced fibrotic responses in fibroblasts and restore SIRT3 levels in mouse models, suggesting its potential as a novel treatment option for systemic scleroderma. Additionally, ACU-D2 has demonstrated promise in neurodegenerative diseases, including Alzheimer's and Parkinson's disease, by addressing mitochondrial dysfunction and improving cognitive function through SIRT3 activation.

Furthermore, Accuitis is exploring the efficacy of ACU-D2 in treating HIV-associated neurocognitive disorders, where it has shown the ability to reverse cognitive abnormalities in preclinical models. The compound's formulation allows for effective systemic administration, including the ability to cross the blood-brain barrier, which is critical for treating central nervous system disorders. In the realm of oncology, their compound ACU-D3 targets vemurafenib-resistant melanoma by normalizing mitochondrial function and demonstrating significant antitumor activity. Overall, Accuitis is advancing a pipeline of first-in-class therapeutics that leverage mitochondrial pathways to address a range of challenging medical conditions.

United States

Accuitis Pharmaceuticals, Inc. is a US registered company with commercial operations located in Atlanta, GA. Accuitis is a participant in the Georgia Research Alliance Venture Lab program and our key technology was discovered by Emory University. We are engaged in the acquisition and development of pharmaceuticals targeting niche, orphan, and underserved disease states. Our lead product is a transformational first in class treatment for Rosacea.

Accuitis

Company Details